Stay updated on Switching to Cabotegravir and Rilpivirine: Clinical Trial

Sign up to get notified when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Switching to Cabotegravir and Rilpivirine: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-13T21:39:43.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study evaluating the efficacy, safety, and tolerability of switching to long-acting Cabotegravir Plus long-acting Rilpivirine from the current antiretroviral regimen in virologically suppressed HIV-1-infected adults.
    Difference
    0.0%
    Check dated 2024-06-06T14:36:05.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    46%
    Check dated 2024-05-22T21:27:42.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:54:53.000Z thumbnail image

Stay in the know with updates to Switching to Cabotegravir and Rilpivirine: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.